46,558 results match your criteria Blood[Journal]


Of mice and men: genes relevant to thrombosis and bleeding.

Blood 2018 Dec;132(24):2532-2534

University of Perugia.

View Article
December 2018

Stressed about erythropoiesis: EBI macrophages.

Authors:
Malay Haldar

Blood 2018 Dec;132(24):2530-2532

University of Pennsylvania.

View Article
December 2018

New wrinkle on deubiquitination in B-cell lymphoma.

Authors:
Siegfried Janz

Blood 2018 Dec;132(24):2529-2530

Medical College of Wisconsin Milwaukee.

View Article
December 2018

Bruton's Tyrosine Kinase degradation as a therapeutic strategy for cancer.

Blood 2018 Dec 13. Epub 2018 Dec 13.

Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, United States;

The covalent Bruton's Tyrosine Kinase (BTK) inhibitor ibrutinib is highly efficacious against multiple B-cell malignancies. However, it is not selective for BTK and multiple mechanisms of resistance, including the C481S-BTK mutation, can compromise its efficacy. We hypothesized that small molecule-induced BTK degradation may overcome some of the limitations of traditional enzymatic inhibitors. Read More

View Article
December 2018
4 Reads

The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for non-malignant diseases.

Blood 2018 Dec 13. Epub 2018 Dec 13.

Fred Hutchinson Cancer Research Center, Seattle, WA, United States;

Despite overall improvements, mortality after allogeneic hematopoietic cell transplantation (HCT) for non-malignant diseases remains a significant problem. We evaluated whether pre-HCT conditions defined by the HCT Comorbidity Index (HCT-CI), predicts probability of post-transplant survival in these patients. Using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, we identified 4,083 patients with non-malignant diseases transplanted between 2007-2014. Read More

View Article
December 2018

Human erythrocyte band 3 is a host receptor for Plasmodium falciparum glutamic acid-rich protein.

Blood 2018 Dec 13. Epub 2018 Dec 13.

Graduate Program in Molecular Microbiology, Sackler School of Graduate Biomedical Sciences, Tufts University School of Medicine, Boston, MA, United States

Malaria remains a major global threat to human health and economic development. Microvascular lesions caused by Plasmodium falciparum-infected human erythrocytes/RBCs are hallmarks of severe pathogenesis contributing to high mortality, particularly in children from sub-Saharan Africa. In this study, we used a phage display cDNA library screening strategy to identify Plasmodium falciparum glutamic acid-rich protein (PfGARP) as a secreted ligand that recognizes an ectodomain of human erythrocyte anion-exchanger, Band 3/AE1, as a host receptor. Read More

View Article
December 2018

How I treat MDS after hypomethylating agent failure.

Authors:
Valeria Santini

Blood 2018 Dec 13. Epub 2018 Dec 13.

MDS Unit, Division of Hematology, AOU Careggi-University of Florence, Florence, Italy, Italy

Hypomethylating agents (HMA), azacitidine and decitabine are standard of care for myelodysplastic syndromes. Response to these agents accounts for around 50% of treated patients and duration of response, although variable, is transient. Prediction of response to HMA is possible with clinical and molecular parameters, but alternative approved treatments are not available and in case of HMA failure, there are no standard therapeutic opportunities. Read More

View Article
December 2018

Affimer proteins as a tool to modulate fibrinolysis, stabilize the blood clot and reduce bleeding complications.

Blood 2018 Dec 13. Epub 2018 Dec 13.

Leeds Institute for Cardiovascular and Metabolic Medicine, School of Medicine, University of Leeds, Leeds, United Kingdom.

Bleeding complications secondary to surgery, trauma, or coagulation disorders are important causes of morbidity and mortality. Although fibrin sealants are considered to minimize blood loss, this is not widely adopted due to high cost and/or risk of infection. We present a novel methodology employing non-antibody fibrinogen-binding proteins, termed Affimers, to stabilize fibrin networks with the potential to control excessive bleeding. Read More

View Article
December 2018

B cell lymphomas present immunoglobulin neoantigens.

Blood 2018 Dec 13. Epub 2018 Dec 13.

Institute for Stem Cell Biology & Regenerative Medicine, Stanford University, Stanford, CA, United States

View Article
December 2018

Extensive Kaposi sarcoma infiltration in bone marrow in a patient with HIV.

Blood 2018 Dec;132(23):2525

The University of Texas MD Anderson Cancer Center.

View Article
December 2018

Stool can soften GVHD.

Blood 2018 Dec;132(23):2429-2430

Amsterdam University Medical Centers.

View Article
December 2018

TLT-1: please release me, let me go.

Authors:
Yotis A Senis

Blood 2018 Dec;132(23):2427-2429

University of Birmingham.

View Article
December 2018

CiTE antibody for AML.

Blood 2018 Dec;132(23):2425-2427

Washington University in St. Louis.

View Article
December 2018

How deep is the myeloma iceberg?

Blood 2018 Dec;132(23):2424-2425

Clinica Universidad de Navarra.

View Article
December 2018

DUO delivers for duvelisib.

Authors:
Jennifer R Brown

Blood 2018 Dec;132(23):2422-2424

Dana-Farber Cancer Institute.

View Article
December 2018

Natural, not immune; classical, not alternative.

Blood 2018 Dec;132(23):2421-2422

McMaster University.

View Article
December 2018

The multifaceted role of fibrinogen in tissue injury and inflammation.

Blood 2018 Dec 6. Epub 2018 Dec 6.

Division of Experimental Hematology and Cancer Biology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital, Cincinnati, OH, United States

The canonical role of the hemostatic and fibrinolytic systems is to maintain vascular integrity. Perturbations in either system can prompt primary pathological endpoints of hemorrhage or thrombosis with vessel occlusion. However, fibrin(ogen) and proteases controlling its deposition and clearance, including (pro)thrombin, and plasmin(ogen), have powerful roles in driving acute and reparative inflammatory pathways that impact the spectrum of tissue injury, remodeling and repair. Read More

View Article
December 2018

Ibrutinib for the treatment of Bing-Neel syndrome: A multicenter study.

Blood 2018 Dec 6. Epub 2018 Dec 6.

Bing Center for Waldenstrom Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States.

The treatment of patients with Bing-Neel syndrome (BNS) is not standardized. We included patients with Waldenstrom macroglobulinemia (WM) and a radiological and/or cytological diagnosis of BNS treated with ibrutinib monotherapy. Response assessment was based on criteria for BNS from the 8th International Workshop for WM. Read More

View Article
December 2018

A novel RAG1 mutation reveals a critical in vivo role for HMGB1/2 during V(D)J recombination.

Blood 2018 Dec 11. Epub 2018 Dec 11.

School of Molecular and Cellular Biology, University of Leeds, Leeds, United Kingdom;

The Recombination Activating Genes, RAG1 and RAG2, are essential for V(D)J recombination and adaptive immunity. Mutations in these genes often cause immunodeficiency, the severity of which reflects the importance of the altered residue(s) during recombination. Here, we describe a novel RAG1 mutation that causes immunodeficiency in an unexpected way: The mutated protein severely disrupts binding of the accessory protein, HMGB1. Read More

View Article
December 2018

and hijack immunoglobulin light chain enhancers in cyclin D1-negative mantle cell lymphoma.

Blood 2018 Dec 11. Epub 2018 Dec 11.

Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain;

Mantle cell lymphoma (MCL) is characterized by the t(11;14)(q13;q32) translocation resulting in overexpression of cyclin D1. However, a small subset of cyclin D1-negative MCL (cyclin D1 MCL) has been recognized, and approximately half of them harbor translocations while the primary event in cyclin D1/D2 MCL remains elusive. To identify other potential mechanisms driving MCL pathogenesis we investigated 56 cyclin D1/SOX11 MCL by fluorescence in situ hybridization (FISH), whole genome/exome sequencing, gene expression and copy number arrays. Read More

View Article
December 2018
10.452 Impact Factor

Transferrin receptor 1 controls systemic iron homeostasis by fine-tuning hepcidin expression to hepatocellular iron load.

Blood 2018 Dec 11. Epub 2018 Dec 11.

Lady Davis Institute for Medical Research, Jewish General Hospital and Department of Medicine, McGill University, Montreal, QC, Canada;

Transferrin receptor 1 (Tfr1) mediates uptake of circulating transferrin-bound iron to developing erythroid cells and other cell types. Its critical physiological function is highlighted by the embryonic lethal phenotype of Tfr1 knockout (Tfrc-/-) mice and the pathologies of several tissue-specific knockouts. We generated Tfrc mice bearing hepatocyte-specific ablation of Tfr1 to explore implications in hepatocellular and systemic iron homeostasis. Read More

View Article
December 2018

Randomized trial of ibrutinib versus ibrutinib plus rituximab in patients with chronic lymphocytic leukemia.

Blood 2018 Dec 7. Epub 2018 Dec 7.

Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX, United States.

Ibrutinib, an oral covalent inhibitor of Bruton's tyrosine kinase (BTK), is an effective therapy for CLL patients. To determine whether rituximab provides added benefit to ibrutinib, we conducted a randomized single center trial of ibrutinib versus ibrutinib plus rituximab. Patients with CLL requiring therapy were randomized to receive 28 day cycles of once-daily ibrutinib 420 mg, either as single agent (n=104), or together with rituximab (375 MG/m, n=104), given weekly during cycle 1, then once per cycle until cycle 6. Read More

View Article
December 2018

Single cell analyses demonstrate that a heme - GATA1 feedback loop regulates red cell differentiation.

Blood 2018 Dec 10. Epub 2018 Dec 10.

Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, United States;

Erythropoiesis is the complex, dynamic, and tightly-regulated process that generates all mature red blood cells. To understand this process, we mapped the developmental trajectories of progenitors from wildtype, erythropoietin-treated and -deleted mice at single cell resolution. Importantly, we linked the quantity of each cell's surface proteins to its total transcriptome, which is a novel method. Read More

View Article
December 2018

The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy.

Blood 2018 Dec 10. Epub 2018 Dec 10.

Department of Hematology and Oncology, University Hospital Tuebingen, Germany;

Anti-leukemia immunity plays an important role in disease control and maintenance of tyrosine kinase inhibitor (TKI)-free remission in chronic myeloid leukemia (CML). Thus, antigen-specific immunotherapy holds promise to strengthen immune control in CML, but requires the identification of CML-associated targets. In this study, we used a mass spectrometry-based approach to identify naturally presented, HLA class I- and class II-restricted peptides in primary CML samples. Read More

View Article
December 2018
10.452 Impact Factor

Decreased median survival of adults with sickle cell disease after adjusting for left truncation bias: a pooled analysis.

Blood 2018 Dec 10. Epub 2018 Dec 10.

Center for Sickle Cell Disease, University of Tennessee Health Science Center, Memphis, TN, United States.

View Article
December 2018

Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphoma.

Blood 2018 Dec 10. Epub 2018 Dec 10.

Department of Pathology, City of Hope Medical Center, Duarte, CA, United States;

The neural transcription factor SOX11 is usually highly expressed in typical mantle cell lymphoma (MCL), but it is absent in the more indolent form of MCL. Despite being an important diagnostic marker for this hard-to-treat malignancy, the mechanisms of aberrant SOX11 expression are largely unknown. Herein, we describe two modes of SOX11 regulation by the cell cycle regulator cyclin D1 (CCND1) and the signal transducer and activator of transcription 3 (STAT3). Read More

View Article
December 2018

An ATF6-tPA pathway in hepatocytes contributes to systemic fibrinolysis and is repressed by DACH1.

Blood 2018 Dec 1. Epub 2018 Dec 1.

Department of Physiology and Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY, United States

Tissue-type plasminogen activator (tPA) is a major mediator of fibrinolysis and thereby prevents excessive coagulation without compromising hemostasis. Studies on tPA regulation have focused on its acute, local release by vascular cells in response to injury or other stimuli. However, very little is known about sources, regulation, and fibrinolytic function of non-injury-induced systemic plasma tPA. Read More

View Article
December 2018
2 Citations
10.452 Impact Factor

Targeting Sirt-1 controls GVHD by inhibiting T-cell allo-response and promoting Treg stability in mice.

Blood 2018 Dec 4. Epub 2018 Dec 4.

Department of Medicine, Medical University of South Carolina, Charleston, SC, United States

Graft-versus-host-disease (GVHD) remains one of the major complications after allogeneic bone marrow transplantation (allo-BMT). Sirtuin-1 (Sirt-1) plays a crucial role in various biological processes including cellular senescence, metabolism and inflammatory responses. Sirt-1 deacetylation regulates different transcription factors that are important for modulating immune responses. Read More

View Article
December 2018
4 Reads

mutations reduce binding of NOTCH1, leading to cleaved NOTCH1 accumulation and target gene activation in CLL.

Blood 2018 Dec 3. Epub 2018 Dec 3.

Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany;

In chronic lymphocytic leukemia (CLL), is mutated in 10% of CLL patients and is associated with poor outcome. However, NOTCH1 activation is identified in approximately half of CLL cases even in the absence of mutations, hence there appears to be additional factors responsible for the impairment of NOTCH1 degradation. The E3 ubiquitin ligase FBXW7 is a negative regulator of NOTCH1 and is mutated in 2-6% of CLL patients. Read More

View Article
December 2018

Novel susceptibility variants at the locus for childhood acute lymphoblastic leukemia in Hispanics.

Blood 2018 Dec 3. Epub 2018 Dec 3.

Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, United States;

Acute lymphoblastic leukemia (ALL) is the most common malignancy in children. Characterized by high levels of Native American ancestry, Hispanics are disproportionally affected by this cancer with high incidence and inferior survival, but the genetic basis for this disparity remains poorly understood because of a paucity of genome-wide investigation of ALL in Hispanics. Performing a genome-wide association study in 940 Hispanic children with ALL and 681 ancestry-matched non-ALL controls, we identified a novel susceptibility locus in the gene (rs2836365; P = 3. Read More

View Article
December 2018

Molecular remission and response patterns in patients with mutant- acute myeloid leukemia treated with enasidenib.

Blood 2018 Dec 3. Epub 2018 Dec 3.

Gustave Roussy, Departement d'hematologie et Departement d'innovation therapeutique, Villejuif, France.

Approximately 8-19% of patients with acute myeloid leukemia (AML) have isocitrate dehydrogenase-2 () mutations, which occur at active site arginine residues, R140 and R172. mutations produce an oncometabolite, 2-hydroxyglutarate (2-HG), that leads to DNA and histone hypermethylation and impaired hematopoietic differentiation. Enasidenib is an oral inhibitor of mutant-IDH2 proteins. Read More

View Article
December 2018
1 Read
10.452 Impact Factor

Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study.

Blood 2018 Dec 3. Epub 2018 Dec 3.

Department of Haematology, Leeds Teaching Hospitals, Leeds, United Kingdom.

Ravulizumab (ALXN1210), a new complement C5 inhibitor, provides immediate, complete, and sustained C5 inhibition. This phase 3, open-label study assessed the noninferiority of ravulizumab to eculizumab in complement inhibitor-naive adults with paroxysmal nocturnal hemoglobinuria (PNH). Patients with lactate dehydrogenase (LDH) ≥1. Read More

View Article
December 2018
1 Read

Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study.

Blood 2018 Dec 3. Epub 2018 Dec 3.

Transplantation (BMT) Unit, Saint-Louis Hospital and University Paris Diderot Paris, France.

Ravulizumab, a new complement C5 inhibitor administered every 8 weeks, was noninferior to eculizumab administered every 2 weeks in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria (PNH). This study assessed noninferiority of ravulizumab to eculizumab in clinically stable PNH patients during previous eculizumab therapy. In this phase 3, open-label, multicenter study, 195 PNH patients on labeled-dose (900 mg every 2 weeks) eculizumab for greater than 6 months were randomly assigned 1:1 to switch to ravulizumab (n = 97) or continue eculizumab (n = 98). Read More

View Article
December 2018
1 Read

Mixed-phenotype acute leukemia, T/megakaryoblastic.

Blood 2018 Nov;132(22):2418

St. Jude Children's Research Hospital.

View Article
November 2018
2 Reads

Ineffective erythropoiesis of TET2 deficiency.

Authors:
Don M Wojchowski

Blood 2018 Nov;132(22):2320-2321

University of New Hampshire.

View Article
November 2018

PMBCL: a molecular diagnosis?

Authors:
Megan S Lim

Blood 2018 Nov;132(22):2319-2320

University of Pennsylvania.

View Article
November 2018

Not so lost in translation: mutations in CLL.

Blood 2018 Nov;132(22):2317-2319

Karolinska Institutet.

View Article
November 2018

An expanding network of cytoskeletal defects.

Authors:
Michael D Keller

Blood 2018 Nov;132(22):2316-2317

Children's National Health System.

View Article
November 2018

Targeting EBV-positive B- and T/NK-cell lymphomas.

Authors:
Heather M Long

Blood 2018 Nov;132(22):2315-2316

University of Birmingham.

View Article
November 2018